multiple myeloma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult male or female patients aged 18 years or older with a confirmed diagnosis of symptomatic newly diagnosed multiple myeloma (NDMM) according to standard criteria. (NCCN 2020.V3) 2. Patient is willing and able to adhere to the study visit schedule(including blood sampling and bone marrow aspiration). 3. Blood routine: absolute neutrophil count (ANC)>= 1.0*10^9/L,platelet count >= 75*10^9/L. Biochemical examination: total bilirubin = 30mL/min (using the Cockroft-Gault equation) 4. Eastern Cooperative Oncology Group Performance Status of 0 to 2.
Exclusion criteria
Exclusion criteria: 1. Ongoing or active infection, known human immunodeficiency virus positive, active hepatitis B or C infection. 2. Psychiatric illness/social situation that would limit compliance with study requirements.Allergy to the study medications, 3. Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, 4. Diagnosis of smodering multiple myeloma, Waldenstroms macroglobulinemia, plasma cell leukemia, POEMS syndrome myelodysplastic syndrome. 5. Cardiac color ultrasound suggests severe pulmonary hypertension (mAP >= 40mmHg), New York Heart association (NYHA) functional class III and above. 6. Diagnosed for another malignancy within 1 year before diagnosis of multiple myeloma; 7. Female patient who is lactating and breastfeeding or has a positive serum pregnancy test during the screening period. 8. Unable to cooperate with or not suitable for PET/CT examination; 9. Acute or sub-acute deep venous thrombosis within 2 weeks. 10. Grade II and above peripheral neuropathy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective remission rate; | — |
Countries
China
Contacts
Renji Hospital, School of Medicine, Shanghai Jiao Tong University,